Eton Pharmaceuticals: The Commercial Model Is Finally Scaling
Seeking Alpha gives Eton Pharmaceuticals a Buy rating, citing 158% third-quarter revenue growth to $57.9 million, a 49% adjusted EBITDA margin, and increased 2026 revenue guidance of more than $175 million. The article identifies LIBERVANT and ASN-001 as growth drivers, with potential launches in 2027 and 2028, respectively.
Why it matters — The reported results, higher guidance, and planned launches highlight the commercial growth and pipeline milestones that ETON watchers may follow.